Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical an...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:237180 |
| Acceso en línea: | https://ddd.uab.cat/record/237180 https://dx.doi.org/urn:doi:10.3324/haematol.2018.200808 |
| Access Level: | acceso abierto |
| Palabra clave: | Adolescent Adult Aged Cohort Studies Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Models, Statistical Myelodysplastic Syndromes Nomograms Prognosis Risk Assessment Risk Factors Survival Rate Transplantation, Homologous Young Adult |
| Sumario: | The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts. |
|---|